Skip to the story

Vol. I · No. 1

Morning ColumnThe letter

Current News · Sourced report

FDA Approves First Plasmid DNA-based Immunotherapy for Adults with Recurrent Respiratory Papillomatosis

The U.S. Food and Drug Administration today granted accelerated approval for Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for treatment of adults with recurrent respiratory papillomatosis (RRP).

News Desk · Oct 30, 2026 · U.S. Food and Drug Administration

Open the source

This item is a public release from the U.S. Food and Drug Administration. The source date is Oct 30, 2026. The next paragraph is the agency's own short text. Morning Column did not rewrite it.

The U.S. Food and Drug Administration today granted accelerated approval for Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for treatment of adults with recurrent respiratory papillomatosis (RRP).

The full release is on the source page. This page is not personal medical advice.

This page is general information from the sources below. It is not personal medical advice, a diagnosis, or a treatment plan. Talk with a qualified clinician about your own health. Read the disclaimer.

References

  1. U.S. Food and Drug Administration. FDA Approves First Plasmid DNA-based Immunotherapy for Adults with Recurrent Respiratory Papillomatosis. Oct 30, 2026.

See a factual error? Write to contact@morningcolumn.com. The corrections log is public.